BioSpace News Archive

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023.

RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Dessislava (Dessy) Boneva, M.D. has joined the Company’s Board of Directors.

TScan Therapeutics, Inc. (Nasdaq: TCRX) today announced the Company will host a virtual key opinion leader (KOL) event on Monday, December 11, at 8:00 a.m. ET to discuss highlights from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m. ET / 11:30 a.m. PT.

Merit Medical Systems, Inc. announced that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of a successful pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) in IgA nephropathy (IgAN).

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.

Abcam plc, a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation for $24.00 per share in cash, to be implemented by way of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, announced that it has commenced an underwritten public offering of $175 million of shares of its common stock.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time.